Greenwich LifeSciences

GLSI

United States

greenwichlifesciences.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GLSI · Stock Price

USD 23.62+14.19 (+150.48%)

Market Cap: $328.7M

Historical price data

Overview

Greenwich LifeSciences is singularly focused on developing GLSI-100, a peptide-based immunotherapy to prevent metastatic recurrence in HER2-positive breast cancer survivors. Its strategy is validated by compelling Phase IIb data showing an 80%+ reduction in recurrence over 5 years and a strong safety profile, which has enabled the launch of a large, global Phase III trial. With a lean operational model, significant insider ownership, and commercial-scale manufacturing already in place, the company is positioned to advance a potential breakthrough in adjuvant cancer care.

OncologyBreast Cancer

Technology Platform

Peptide-based active immunotherapy platform designed to stimulate targeted CD8+ T-cell responses against specific tumor-associated antigens (HER2/neu), utilizing synthetic peptides and immune adjuvants like GM-CSF.

Pipeline

1 drug in pipeline1 in Phase 3

Drug	Indication	Stage	Watch
Placebo + GLSI-100	Breast Cancer	Phase 3

Opportunities

GLSI-100 addresses a multi-billion dollar unmet need in preventing breast cancer recurrence.

Success could establish a new therapeutic class (adjuvant cancer vaccine) and create opportunities for label expansion into non-HLA-A*02 patients and other HER2-positive cancers.

Existing commercial-scale manufacturing provides a significant first-mover and operational advantage.

Risk Factors

The company faces extreme binary risk on its single Phase III trial outcome.

Regulatory hurdles, potential failure to replicate stellar Phase IIb results, and challenges in commercializing a novel vaccine in a crowded adjuvant therapy market are significant threats.

The company's financial sustainability depends on successful trial outcomes and likely future capital raises.

Competitive Landscape

GLSI-100's primary competition is the current standard of care (trastuzumab, pertuzumab, ADCs like Enhertu), which it aims to complement, not replace. It has a first-mover advantage as the only Phase III active immunotherapy for this specific adjuvant prevention indication, with other vaccine approaches in earlier development stages.